Novel CNS Biomarkers Summit Europe

Europe is rapidly becoming a hub for next-generation CNS biomarker innovation, with advances in blood-based, digital and multimodal biomarkers transforming neurological drug development.

That’s why the Novel CNS Biomarkers Summit Europe comes at a timely moment, bringing together Europe's leading biomarker, translational medicine, neuroscience and clinical development experts to tackle one of the industry's biggest challenges: improving clinical trial success in CNS drug development.

Join Roche, Lundbeck, UCB, Servier, Immunic Therapeutics and 60+ attendees gathering at Europe’s only conference dedicated exclusively to advancing ultrasensitive fluid, imaging and digital biomarkers for CNS drug development.

FREE* Conference Passes available for eligible biopharma: Secure your FREE* pass here.

With 2 interactive workshops, a leading global speaker faculty, and 6+ CNS indications covered across Alzheimer's, Parkinson's, ALS, epilepsy, schizophrenia and MSA, here's what you'll gain from attending:

Strengthen biomarker validation and harmonisation by exploring assay validation, multi-vendor platforms, QC, reference materials and regulatory-grade biomarker packages
Evaluate next-generation fluid biomarkers including α-Synuclein SAA, p-tau217, toxic oligomers, SV2A and blood-based alternatives to CSF
Build multimodal biomarker strategies by bringing together fluid biomarkers, MRI, PET, EEG, digital cognition and remote monitoring
Address practical implementation challenges including alternatives to lumbar puncture, peripheral sampling, global sample collection, processing and cross-site consistency
See how leading CNS programmes are applying these approaches through insights from teams at Roche, Lundbeck, UCB, Saniona, NRG Therapeutics, Servier and others